RxDoctor Payments Data

Priya Roy, MD

Internal Medicine · New Britain, CTNPI 1730120494

Payments from drug & device makers

$3,520in general payments, 2019–2025

Across 175 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$702
  • Novo Nordisk$418
  • Pfizer$404
  • AbbVie$329
  • Lilly USA, LLC$316
  • Abiomed$150
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,520 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$83,401
Medicare patients
201
Services billed
866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin79$112,311
OzempicSemaglutide108$102,672
FarxigaDapagliflozin Propanediol57$72,598
MounjaroTirzepatide23$24,237
EliquisApixaban27$23,330
XareltoRivaroxaban27$19,763
TrulicityDulaglutide11$10,297
SynthroidLevothyroxine Sodium42$4,068
Rosuvastatin Calcium294$4,004
Atorvastatin Calcium421$3,350
Losartan Potassium407$3,252
Metoprolol Succinate240$2,963
Levothyroxine Sodium355$2,956
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,873
Amlodipine Besylate450$2,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$118$112,31179 claims
Novo NordiskOzempic$418$102,672108 claims
AstraZenecaFarxiga$702$72,59857 claims
Lilly USA, LLCMounjaro, Trulicity$316$34,53434 claims
PfizerEliquis$404$23,33027 claims
Johnson & JohnsonXarelto$57$19,76327 claims
AbbVieSynthroid$329$4,06842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →